# CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin Syndrome

> **NCT04893486** · PHASE2 · COMPLETED · sponsor: **Palvella Therapeutics, Inc.** · enrollment: 73 (actual)

## Conditions studied

- BCCs in Gorlin Syndrome Patients

## Interventions

- **DRUG:** PTX-022
- **DRUG:** Vehicle comparator

## Key facts

- **NCT ID:** NCT04893486
- **Lead sponsor:** Palvella Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-06
- **Primary completion:** 2023-03-13
- **Final completion:** 2023-03-13
- **Target enrollment:** 73 (ACTUAL)
- **Last updated:** 2024-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04893486

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04893486, "CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin Syndrome". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04893486. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*